These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31793165)

  • 1. Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
    Meier JJ; Menge BA; Schenker N; Erdmann S; Kahle-Stephan M; Schliess F; Kapitza C; Nauck MA
    Diabetes Obes Metab; 2020 Apr; 22(4):599-611. PubMed ID: 31793165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
    Lorenz M; Pfeiffer C; Steinsträsser A; Becker RH; Rütten H; Ruus P; Horowitz M
    Regul Pept; 2013 Aug; 185():1-8. PubMed ID: 23665027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
    Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
    Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
    Tonneijck L; Muskiet MHA; Twisk JW; Kramer MHH; Danser AHJ; Joles JA; Smits MM; van Raalte DH
    Hypertension; 2018 Aug; 72(2):314-322. PubMed ID: 29915021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
    Rayner CK; Watson LE; Phillips LK; Lange K; Bound MJ; Grivell J; Wu T; Jones KL; Horowitz M; Ferrannini E; Tricò D; Frascerra S; Mari A; Natali A
    Diabetes Care; 2020 Aug; 43(8):1813-1821. PubMed ID: 32471908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
    Meier JJ; Rosenstock J; Hincelin-Méry A; Roy-Duval C; Delfolie A; Coester HV; Menge BA; Forst T; Kapitza C
    Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.
    Juel CTB; Lund A; Andersen MM; Hansen CP; Storkholm JH; Rehfeld JF; van Hall G; Hartmann B; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
    Diabetologia; 2020 Jul; 63(7):1285-1298. PubMed ID: 32394228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
    Ahrén B; Gautier JF; Berria R; Stager W; Aronson R; Bailey CJ
    Diabetes Obes Metab; 2014 Sep; 16(9):861-8. PubMed ID: 24641271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lixisenatide as add-on therapy to basal insulin.
    Brown DX; Butler EL; Evans M
    Drug Des Devel Ther; 2013 Dec; 8():25-38. PubMed ID: 24363554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.
    Gautier T; Umpierrez G; Renard E; Kovatchev B
    J Diabetes Sci Technol; 2021 Mar; 15(2):371-376. PubMed ID: 31810389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
    Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
    Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.
    Jones KL; Rigda RS; Buttfield MDM; Hatzinikolas S; Pham HT; Marathe CS; Wu T; Lange K; Trahair LG; Rayner CK; Horowitz M
    Diabetes Obes Metab; 2019 May; 21(5):1158-1167. PubMed ID: 30623563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lixisenatide (Lyxumia), a new agonist of glucagon-like peptide-1 receptors with a predominant postprandial action].
    Scheen AJ
    Rev Med Liege; 2014 Feb; 69(2):102-9. PubMed ID: 24683832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
    Becker RH; Stechl J; Msihid J; Kapitza C
    Diabetes Obes Metab; 2014 Sep; 16(9):793-800. PubMed ID: 24521245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)].
    Scheen AJ
    Rev Med Liege; 2019 Feb; 74(2):111-116. PubMed ID: 30793566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes.
    Scott LJ
    Drugs; 2017 Aug; 77(12):1353-1362. PubMed ID: 28667587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.